Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

9480	Companies
185559	Keywords
117951	Articles
99390	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 07/28/2025 at 13:05, 4 months 8 days ago

Moderna présentera ses données thérapeutiques à base d'ARNm au congrès de l'ESMO 2025

Cancer De La Vessie Moderne Mélanome Thérapies À Base D'ARNm Congrès ESMO 2025
PRESS RELEASE

published on 07/28/2025 at 13:00, 4 months 8 days ago

Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene

Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF

published on 07/25/2025 at 14:50, 4 months 11 days ago

L'EMA recommande le vaccin COVID-19 mis à jour de Moderna pour une autorisation européenne

Moderne Vaccin Contre Le Covid-19 Commission Européenne Approbation De L'EMA SARS-CoV-2 LP.8.1
BRIEF

published on 07/25/2025 at 14:50, 4 months 11 days ago

EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE

published on 07/25/2025 at 14:45, 4 months 11 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season

COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF

published on 06/30/2025 at 13:05, 5 months 5 days ago

Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010
BRIEF

published on 06/30/2025 at 13:05, 5 months 5 days ago

Moderna annonce des résultats positifs de phase 3 pour son vaccin contre la grippe saisonnière

Moderne Vaccin Contre La Grippe Résultats De La Phase 3 RVE ARNm-1010
PRESS RELEASE

published on 06/30/2025 at 13:00, 5 months 5 days ago

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated 26.6% higher vaccine efficacy than standard seasonal flu vaccine in adults 50+. Strong rVE observed for all strains. Moderna announces positive Phase 3 results for mRNA-1010 flu vaccine

Moderna Phase 3 Seasonal Influenza MRNA-1010 Vaccine Efficacy
BRIEF

published on 06/13/2025 at 01:30, 5 months 22 days ago

Le vaccin contre le VRS de Moderna, mRESVIA, obtient l'approbation de la FDA pour les jeunes adultes à risque

Approbation De La FDA Maladies Chroniques Moderne Vaccin Contre Le VRS MRESVIA
BRIEF

published on 06/13/2025 at 01:30, 5 months 22 days ago

Moderna's RSV Vaccine, mRESVIA, Gains FDA Approval for Younger At-Risk Adults

FDA Approval Chronic Conditions Moderna RSV Vaccine MRESVIA

Accesswire

Published on 12/05/2025 at 21:45, 1 hour 5 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 1 hour 20 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 30 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 50 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours 25 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 34 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 38 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 52 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 4 hours 23 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 4 hours 34 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 17:18, 5 hours 32 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 5 hours 32 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 39 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 7 hours 39 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 51 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE